Beroterkib is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Beroterkib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Beroterkib overview
Beroterkib (ASTX-029) is under development for the treatment of advanced or refractory solid tumors including melanoma, myelodysplastic syndrome, chronic myeloid leukemia, chronic myelomonocytic leukemia, and non-small cell lung cancer. It is administered through oral route. It acts by targeting extracellular signal-regulated kinases 1 and 2 (ERK1/2). The drug candidate is being developed based on pyramid technology.
Taiho Pharmaceutical overview
Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, is a global pharmaceutical company primarily engaged in the research, development, and supply of pharmaceutical products. The company’s main activities include the development of innovative drugs, particularly in the areas of oncology and immune-related diseases. Taiho’s major products include a range of prescription drugs, such as Lonsurf and other consumer healthcare products. The company serves a broad customer base, including patients, healthcare professionals, and medical staff, providing solutions for various health conditions and diseases. The company’s products are available worldwide. Taiho operates globally, with business locations in the US, Europe, Asia, and Oceania. Taiho is headquartered in Tokyo, Japan.
For a complete picture of Beroterkib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
